In March 2025, PepsiCo paid $1.95 billion for a soda company that puts 2 grams of prebiotic fiber in every can. Net of tax benefits, the deal came to $1.65 billion, according to CNBC. Four months later, Poppi agreed to pay $8.9 million to settle a class action lawsuit alleging that the gut health claims behind that same can were overstated, according to Wikipedia. Both things are true. Neither one cancels the other out.
That contradiction is the story. A company can build a $500 million revenue business, as Poppi did in 2024 after doing $100 million the year before according to StartupBooted, on a health claim that a court settlement never actually validated. It can sell to the largest snack and beverage company in the world at a valuation north of what most venture-backed consumer brands ever see, and still leave the underlying scientific question open. For founders building in wellness categories, and for the investors who fund them, that gap between commercial outcome and scientific proof is now the central risk to price into every deal.
The kitchen experiment that became a category
Allison Ellsworth started making a version of Poppi at home, mixing apple cider vinegar into drinks to manage her own digestive issues. In 2018, nine months pregnant, she pitched it on Shark Tank and walked away with $400,000 from Rohan Oza for 25% equity, according to femfounded.org. That stake, and the deal structure around it, set the template for a company that would raise relatively little institutional capital and still produce an outsized exit. Poppi raised $13.5 million in a Series A led by CAVU Consumer Partners in August 2021, then $25 million in a Series B in December 2022, for $39.3 million total across all funding rounds according to PitchBook and CNBC.
Run the math on that against the sale price. A company that raised under $40 million sold for $1.95 billion. The Ellsworths owned roughly 12% at the time of sale and netted about $150 million post-tax, per femfounded.org. That return profile is why every consumer-focused VC fund spent 2023 and 2024 looking for the next prebiotic soda, and why PepsiCo was willing to pay a premium multiple for a brand that TikTok had already done the marketing work for.
The 2-gram problem
Here is the number that matters most, and the one the lawsuit turned on: Poppi contains 2 grams of prebiotic fiber per 12-ounce can. The class action argued that amount is too low to deliver a meaningful gut health benefit, according to femfounded.org. Compare that to Olipop, Poppi's closest competitor, which packs 9 grams of prebiotic fiber per can, positioning it above the threshold where research supports digestive benefits, per the same source.
Poppi settled for $8.9 million in July 2025 without admitting fault, according to Wikipedia and femfounded.org. A settlement is not a verdict. It resolves litigation risk, not scientific uncertainty. That distinction gets lost in headlines that treat the payout as an admission, and it gets lost again by anyone who assumes the settlement proves the opposite, that Poppi's marketing was innocent all along. Neither reading is supported by what actually happened: a company paid to make a lawsuit go away, and the underlying question of whether 2 grams does anything meaningful was never adjudicated.
The strongest case for Poppi's science
The steelman here deserves a full hearing, because it's not weak. Prebiotic fiber research generally examines doses in the 2 to 4 gram range as typical market concentrations, and multiple studies suggest that even modest doses at this level promote growth of beneficial gut bacteria. If that's the operative research finding, then Poppi's 2 grams sits inside, not below, the range where effects have been observed. The lawsuit's framing, that 2 grams is definitionally insufficient, assumes a threshold that the broader research doesn't clearly establish as a hard cutoff.
There's a second piece of the opposing case, and it's arguably stronger: Olipop's 9 grams didn't drive its growth any more than Poppi's 2 grams drove Poppi's. Olipop positioned itself as a direct replacement for traditional soda flavors, going after Coke and Dr Pepper drinkers on taste and nostalgia. Poppi won on a different axis entirely, becoming the number-one best-selling soda on Amazon and capturing 19% share of the prebiotic soda market through viral TikTok content and celebrity partnerships. If taste, packaging, and influencer reach are what actually moved half a billion dollars in revenue, then the fiber count was never the product. It was the receipt customers used to justify a purchase they were already going to make.
This is a meaningful distinction for anyone evaluating a wellness brand's durability. If the science is genuinely unsettled in Poppi's favor, or if the science was never the growth driver in the first place, then the lawsuit is a marketing and legal footnote, not evidence of a fraudulent product. Operators inside the functional beverage category report, anecdotally, that reformulation conversations happen constantly regardless of litigation exposure, because the category moves fast and competitors keep raising the fiber bar. That's a market dynamic, not proof of guilt.
Why the distinction still matters for the money
Where the opposing case runs out of road is on the specific legal exposure, not the general science. A brand can be operating inside a defensible research range and still lose a class action, because false advertising law in most jurisdictions turns on what was claimed in marketing copy, not on what a meta-analysis of prebiotic dosing would conclude. Poppi's exposure came from language on packaging and in ads that implied a level of gut health benefit the settlement suggests the company could not fully defend in court, expensive enough to negotiate away for $8.9 million rather than litigate to a verdict.
That's the operative lesson for any founder in this category: the research showing 2 to 4 grams can be effective is not the same claim as "this specific can, marketed this specific way, delivers this specific benefit." Plaintiffs' attorneys target the marketing language, not the dosing literature. A company can be scientifically defensible in the aggregate and still be commercially exposed because of how a label reads.
The market that made this exit possible
None of this happened in a vacuum. The global digestive health market was valued at $68.15 billion in 2026 and is projected to reach $142.92 billion by 2034, a 9.7% compound annual growth rate, according to Fortune Business Insights. That trajectory is what made a $1.95 billion price tag rational for PepsiCo in the first place. The company wasn't just buying a beverage brand with $500 million in trailing revenue. It was buying a foothold in a category on pace to more than double over the next eight years, with a customer base already trained by Poppi's own marketing to associate the product with a health outcome.
That's the position institutional buyers are actually underwriting: not the current science, but the growth curve of consumer belief in gut health as a category. PepsiCo's own diligence team almost certainly modeled the litigation risk before closing. The $300 million gap between the headline $1.95 billion and the net $1.65 billion after tax benefits suggests deal structuring that accounted for exactly this kind of exposure, according to CNBC.
Who this actually benefits
The Ellsworths benefit most directly: roughly $150 million post-tax on a 12% stake, for a company they started by mixing apple cider vinegar in a kitchen. Early institutional backers, particularly CAVU Consumer Partners, who led the $13.5 million Series A in 2021, saw a return that justifies the entire fund thesis of betting on founder-led wellness brands before they scale. PepsiCo benefits from a five-year head start in a market projected to grow 9.7% annually through 2034, purchased at a price that already discounts some of the legal risk. The parties who come out weaker are the plaintiffs in the class action, whose $8.9 million settlement, split across a class, works out to a fraction of what any individual consumer paid in a premium price for cans they bought believing in a specific health claim.
Where this recommendation fails
The lesson here isn't "gut health claims are fine as long as your lawyers are good." It fails in a specific way: if a brand's growth is genuinely built on a health claim rather than taste or brand equity, and that claim turns out to be unsupported at the dose being sold, the exit multiple collapses along with consumer trust once the science becomes common knowledge. Poppi's bet worked because enough of its value came from things other than the 2 grams: the Shark Tank origin story, the TikTok virality, the Amazon bestseller status. A brand with weaker distribution and no other differentiator, riding purely on a fiber count that later gets challenged, does not have PepsiCo's balance sheet to absorb an $8.9 million settlement as a rounding error on a $1.95 billion deal.
The founders who are watching this exit closely and asking whether to lean harder into a health claim or hedge with brand-building elsewhere already have their answer in the math. Poppi's outcome rewarded the brand, not the biology. The next founder in this category has to decide which one they're actually selling.